Your browser doesn't support javascript.
loading
Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE).
Kundranda, M; Gracian, A C; Zafar, S F; Meiri, E; Bendell, J; Algül, H; Rivera, F; Ahn, E R; Watkins, D; Pelzer, U; Charu, V; Zalutskaya, A; Kuesters, G; Pipas, J M; Santillana, S; Askoxylakis, V; Ko, A H.
Affiliation
  • Kundranda M; Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, USA.
  • Gracian AC; Medical Oncology, Centro Integral Oncologico Clara Campal, Madrid, Spain; Departamento de Ciencias Médicas Clínicas, Universidad CEU San Pablo, Madrid, Spain.
  • Zafar SF; Hematology and Oncology, Florida Cancer Specialists, Fort Myers, USA.
  • Meiri E; Medical Oncology, Comprehensive Care and Research Center, Atlanta, USA.
  • Bendell J; GI Oncology, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, USA.
  • Algül H; TUM School of Medicine, Klinikum rechts der Isar, Medizinische Klinik II, Technical University of Munich, Munich, Germany.
  • Rivera F; Medical Oncology, Hospital Universitario Marques de Valdecilla, Santander, Spain.
  • Ahn ER; Medical Oncology, Cancer Treatment Centers of America Chicago, Zion, USA.
  • Watkins D; Department of Medicine, Royal Marsden Hospital, Sutton, UK.
  • Pelzer U; Charité - Universitätsmedizin Berlin, Germany.
  • Charu V; Hematology/Oncology, Pacific Cancer Medical Center, Anaheim, USA.
  • Zalutskaya A; Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA.
  • Kuesters G; Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA.
  • Pipas JM; Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA.
  • Santillana S; Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA.
  • Askoxylakis V; Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA.
  • Ko AH; Hematology/Oncology, University of California San Francisco Cancer Center, San Francisco, USA. Electronic address: andrew.ko@ucsf.edu.
Ann Oncol ; 31(1): 79-87, 2020 01.
Article in En | MEDLINE | ID: mdl-31912800
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Antineoplastic Combined Chemotherapy Protocols Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2020 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Antineoplastic Combined Chemotherapy Protocols Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2020 Type: Article Affiliation country: United States